Clinical trial NCT02593682 - References

Panic Disorder — The Role of Orexin in Human Panic Disorder

Citation(s)

•   Bertani A, Caldirola D, Bussi R, Bellodi L, Perna G
  The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study. J Clin Psychopharmacol. 2001 Jun;21(3):262-7.
•   Bonaventure P, Yun S, Johnson PL, Shekhar A, Fitz SD, Shireman BT, Lebold TP, Nepomuceno D, Lord B, Wennerholm M, Shelton J, Carruthers N, Lovenberg T, Dugovic C
  A selective orexin-1 receptor antagonist attenuates stress-induced hyperarousal without hypnotic effects. J Pharmacol Exp Ther. 2015 Mar;352(3):590-601. doi: 10.1124/jpet.114.220392. Epub 2015 Jan 12.
•   Brundin L, Björkqvist M, Petersén A, Träskman-Bendz L
  Reduced orexin levels in the cerebrospinal fluid of suicidal patients with major depressive disorder. Eur Neuropsychopharmacol. 2007 Sep;17(9):573-9. Epub 2007 Mar 7.
•   Coryell W, Arndt S
  The 35% CO2 inhalation procedure: test-retest reliability. Biol Psychiatry. 1999 Apr 1;45(7):923-7.
•   de Lecea L, Sutcliffe JG
  The hypocretins/orexins: novel hypothalamic neuropeptides involved in different physiological systems. Cell Mol Life Sci. 1999 Oct 30;56(5-6):473-80. Review.
•   Deadwyler SA, Porrino L, Siegel JM, Hampson RE
  Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci. 2007 Dec 26;27(52):14239-47.
•   Flores Á, Valls-Comamala V, Costa G, Saravia R, Maldonado R, Berrendero F
  The hypocretin/orexin system mediates the extinction of fear memories. Neuropsychopharmacology. 2014 Nov;39(12):2732-41. doi: 10.1038/npp.2014.146. Epub 2014 Jun 16.
•   Goddard AW, Ball SG, Martinez J, Robinson MJ, Yang CR, Russell JM, Shekhar A
  Current perspectives of the roles of the central norepinephrine system in anxiety and depression. Depress Anxiety. 2010 Apr;27(4):339-50. doi: 10.1002/da.20642. Review.
•   Goddard AW, Mason GF, Almai A, Rothman DL, Behar KL, Petroff OA, Charney DS, Krystal JH
  Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry. 2001 Jun;58(6):556-61.
•   Goddard AW, Woods SW, Sholomskas DE, Goodman WK, Charney DS, Heninger GR
  Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res. 1993 Aug;48(2):119-33.
•   Herring WJ, Snyder E, Budd K, Hutzelmann J, Snavely D, Liu K, Lines C, Roth T, Michelson D
  Orexin receptor antagonism for treatment of insomnia: a randomized clinical trial of suvorexant. Neurology. 2012 Dec 4;79(23):2265-74. doi: 10.1212/WNL.0b013e31827688ee. Epub 2012 Nov 28.
•   Johnson PL, Samuels BC, Fitz SD, Lightman SL, Lowry CA, Shekhar A
  Activation of the orexin 1 receptor is a critical component of CO2-mediated anxiety and hypertension but not bradycardia. Neuropsychopharmacology. 2012 Jul;37(8):1911-22. doi: 10.1038/npp.2012.38. Epub 2012 Mar 28.
•   Johnson PL, Truitt W, Fitz SD, Minick PE, Dietrich A, Sanghani S, Träskman-Bendz L, Goddard AW, Brundin L, Shekhar A
  A key role for orexin in panic anxiety. Nat Med. 2010 Jan;16(1):111-5. doi: 10.1038/nm.2075. Epub 2009 Dec 27.
•   Johnson PL, Truitt WA, Fitz SD, Lowry CA, Shekhar A
  Neural pathways underlying lactate-induced panic. Neuropsychopharmacology. 2008 Aug;33(9):2093-107. Epub 2007 Dec 5.
•   Kato H, Hosoda H, Fukuda T, Masushige S, Kida S
  Characterization of the promoter of the mouse preproorexin gene. Biosci Biotechnol Biochem. 2007 Mar;71(3):840-3. Epub 2007 Mar 7.
•   Keller MB, Hanks DL
  Course and outcome in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 1993 Jul;17(4):551-70. Review.
•   Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS
  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry. 1994 Jan;51(1):8-19.
•   Levine L, Gaydos B, Sheehan D, et al
  The mGlu2/3 receptor agonist, LY354740, reduces panic anxiety induced by a CO2 challenge in patients diagnosed wityh panic disorder. Neuropharmacology. 2002;43(2):294.
•   Long Z, Medlock C, Dzemidzic M, Shin YW, Goddard AW, Dydak U
  Decreased GABA levels in anterior cingulate cortex/medial prefrontal cortex in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jul 1;44:131-5. doi: 10.1016/j.pnpbp.2013.01.020. Epub 2013 Feb 4.
•   Markowitz JS, Weissman MM, Ouellette R, Lish JD, Klerman GL
  Quality of life in panic disorder. Arch Gen Psychiatry. 1989 Nov;46(11):984-92.
•   Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, Walsh JK, Krystal AD, Benca RM, Cohn M, Lines C, Roth T, Herring WJ
  Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014 May;13(5):461-71. doi: 10.1016/S1474-4422(14)70053-5. Epub 2014 Mar 27.
•   Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, Vankova J, Black J, Harsh J, Bassetti C, Schrader H, Nishino S
  The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol. 2002 Oct;59(10):1553-62.
•   Montgomery SA, Asberg M
  A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9.
•   Papp LA, Klein DF, Martinez J, Schneier F, Cole R, Liebowitz MR, Hollander E, Fyer AJ, Jordan F, Gorman JM
  Diagnostic and substance specificity of carbon-dioxide-induced panic. Am J Psychiatry. 1993 Feb;150(2):250-7.
•   Perna G, Barbini B, Cocchi S, Bertani A, Gasperini M
  35% CO2 challenge in panic and mood disorders. J Affect Disord. 1995 Mar 14;33(3):189-94.
•   Perna G, Battaglia M, Garberi A, Arancio C, Bertani A, Bellodi L
  Carbon dioxide/oxygen challenge test in panic disorder. Psychiatry Res. 1994 May;52(2):159-71.
•   Pollack MH, Otto MW, Rosenbaum JF, Sachs GS, O'Neil C, Asher R, Meltzer-Brody S
  Longitudinal course of panic disorder: findings from the Massachusetts General Hospital Naturalistic Study. J Clin Psychiatry. 1990 Dec;51 Suppl A:12-6.
•   Roy-Byrne PP, Stang P, Wittchen HU, Ustun B, Walters EE, Kessler RC
  Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br J Psychiatry. 2000 Mar;176:229-35.
•   Sakurai T
  The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness. Nat Rev Neurosci. 2007 Mar;8(3):171-81. Epub 2007 Feb 14. Review.
•   Salomon RM, Ripley B, Kennedy JS, Johnson B, Schmidt D, Zeitzer JM, Nishino S, Mignot E
  Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects. Biol Psychiatry. 2003 Jul 15;54(2):96-104.
•   Samson WK, et al
  Both type 1 and type 2 receptors transmit the behavioral effects of orexin/hypocretin. The FASEB Journal. 2007;21(5):A462.
•   Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ
  LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress. 2003 Sep;6(3):189-97. Review.
•   Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SW, Gorman JM, Papp LA
  Multicenter collaborative panic disorder severity scale. Am J Psychiatry. 1997 Nov;154(11):1571-5.
•   Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC
  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57. Review.
•   Shekhar A, Keim SR, Simon JR, McBride WJ
  Dorsomedial hypothalamic GABA dysfunction produces physiological arousal following sodium lactate infusions. Pharmacol Biochem Behav. 1996 Oct;55(2):249-56.
•   Shin YW, Dzemidzic M, Jo HJ, Long Z, Medlock C, Dydak U, Goddard AW
  Increased resting-state functional connectivity between the anterior cingulate cortex and the precuneus in panic disorder: resting-state connectivity in panic disorder. J Affect Disord. 2013 Sep 25;150(3):1091-5. doi: 10.1016/j.jad.2013.04.026. Epub 2013 May 17.
•   Strawn JR, Pyne-Geithman GJ, Ekhator NN, Horn PS, Uhde TW, Shutter LA, Baker DG, Geracioti TD Jr
  Low cerebrospinal fluid and plasma orexin-A (hypocretin-1) concentrations in combat-related posttraumatic stress disorder. Psychoneuroendocrinology. 2010 Aug;35(7):1001-7. doi: 10.1016/j.psyneuen.2010.01.001. Epub 2010 Feb 8. Erratum in: Psychoneuroendocrinology. 2016 Jan;63:410.
•   Sun H, Kennedy WP, Wilbraham D, Lewis N, Calder N, Li X, Ma J, Yee KL, Ermlich S, Mangin E, Lines C, Rosen L, Chodakewitz J, Murphy GM
  Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep. 2013 Feb 1;36(2):259-67. doi: 10.5665/sleep.2386.
•   Thompson JP, Watt P, Sanghavi S, Strupish JW, Lambert DG
  A comparison of cerebrospinal fluid and plasma urotensin II concentrations in normotensive and hypertensive patients undergoing urological surgery during spinal anesthesia: a pilot study. Anesth Analg. 2003 Nov;97(5):1501-3.
•   van Beek N, Griez E
  Reactivity to a 35% CO2 challenge in healthy first-degree relatives of patients with panic disorder. Biol Psychiatry. 2000 May 1;47(9):830-5.
•   Weissman MM, Bland RC, Canino GJ, Faravelli C, Greenwald S, Hwu HG, Joyce PR, Karam EG, Lee CK, Lellouch J, Lépine JP, Newman SC, Oakley-Browne MA, Rubio-Stipec M, Wells JE, Wickramaratne PJ, Wittchen HU, Yeh EK
  The cross-national epidemiology of panic disorder. Arch Gen Psychiatry. 1997 Apr;54(4):305-9.
•   Weissman MM, Klerman GL, Markowitz JS, Ouellette R
  Suicidal ideation and suicide attempts in panic disorder and attacks. N Engl J Med. 1989 Nov 2;321(18):1209-14.
•   Williams RH, Jensen LT, Verkhratsky A, Fugger L, Burdakov D
  Control of hypothalamic orexin neurons by acid and CO2. Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10685-90. Epub 2007 Jun 11.

The Role of Orexin in Human Panic Disorder

Details for clinical trial NCT02593682